'/%3E%3C/svg%3E%0A){kind=small}
Fueled by a deep scientific expertise built over decades of research, Prothena is integrating scientific insights around protein dysregulation to advance a pipeline of therapeutic candidates for a number of neurodegenerative and rare peripheral amyloid diseases which affect millions of people and their families worldwide.
Program/Indication
Protein Target
Discovery
Pre-clinical
Phase 1
Phase 2
Phase 3
Global Partner2
PrasinezumabParkinson’s disease
α-Synuclein
(C-terminus)
Transthyretin
(misTTR)
PRX019Neurodegeneration
Undisclosed Target
¹ Orphan Drug Designation granted by FDA & EMA; ² In July 2021 Novo Nordisk acquired coramitug (formerly PRX004) and broader ATTR amyloidosis program and gained full worldwide rights. Prothena is eligible to receive up to $1.23 billion in total consideration.
Neurodegenerative
Rare Peripheral
